Retatrutide Stability Research

Independent Research Disclaimer: External research summarised on this page was not conducted or commissioned by Solatide Biosciences. Results relate to the specific materials and experimental conditions tested and should not be interpreted as a stability specification for Solatide products. All Solatide Biosciences materials are supplied strictly for in vitro laboratory research use only.

Research Overview

This page summarises analytical stability testing on retatrutide samples compiled and published by PepRecon, an independent research and education platform. The underlying studies were designed, funded and run by PTDS (a crowdsourced research peptide testing community). PepRecon serves as host and publisher of the findings; it is not the laboratory or original research organisation. Independent third-party analytical laboratories were used for testing. Janoshik is specifically identified as the analytical laboratory for the heat-stress experiment (Test 293).

The published article is: "Retatrutide: The Complete Stability Picture", published 13 September 2026 by PepRecon. View the source article at peprecon.com →

Eight separate analytical experiments were conducted at different times, involving different vendors, lots, nominal quantities, conditions and testing intervals. They do not constitute a single controlled pharmaceutical stability programme. Comparisons involving the same product or kit are therefore generally more informative than comparisons across unrelated tests.

How Stability Was Measured: Mass vs Purity

Two distinct analytical measurements appear throughout this data. Understanding the difference is essential for interpreting the results correctly.

Recovered Peptide Mass

The total quantity of peptide measurably recovered from the sample during analysis. A decrease indicates loss of recoverable material, which may include aggregated or insoluble peptide removed during sample preparation.

HPLC Purity

The proportion of chromatographically detected material that corresponds to the primary peptide peak. Reflects compositional quality of the soluble fraction analysed, but does not measure total peptide recovered.

Stability

A broader concept that cannot responsibly be reduced to either measurement alone. A sample may show high HPLC purity while having lost a meaningful proportion of recoverable mass.

Important: Solution samples may be filtered before analytical testing to protect instruments. Insoluble degradation products or aggregates can be removed in this step. The remaining soluble material may therefore show very high HPLC purity even though total recovered peptide has fallen. 99% purity does not mean 99% of the original peptide remains. For solution-state stability, recovered peptide mass is particularly informative. For dry lyophilised material, purity can be more directly informative as aqueous aggregation is not occurring.

Refrigerated Solution Data

The following tests examined retatrutide samples stored in refrigerated solution conditions. All data is sourced from PTDS community testing compiled by PepRecon. Results relate to the specific samples and conditions tested.

Test 555 — SSA Retatrutide 30 mg (Purple Cap) N=1

Diluent: Bacteriostatic water  |  Timepoints tested: Day 0, 30, 45, 60

The article reports that this later SSA batch maintained greater than 99.4% HPLC purity through 60 days of refrigerated storage. Individual mass measurements for this test were not reported in the source material.

Test 683 — J5-ZYH Retatrutide 60 mg (Bacteriostatic Water Arm) N=1

Diluent: Bacteriostatic water (Hospira)  |  Timepoints tested: Day 0, 30, 60, 90

Timepoint Recovered Peptide Mass Change from Day 0
Day 0 64.98 mg —
Day 90 63.40 mg −2.4%

Intermediate timepoint mass values (Day 30, Day 60) were not supplied in the source data and have not been interpolated.

Test 616 — GBBB-ZJC Retatrutide 60 mg, Two Vials N=2 same product

Diluent: Bacteriostatic water  |  Timepoints tested: Day 0, 30, 45, 60, 90

Vial Mass Retained at Day 90 Approximate Mass Loss HPLC Purity
Vial 1 91.0% ~9% Approx. 99.6%
Vial 2 90.4% ~10% Approx. 99.6%
Note: Test 616 clearly illustrates the mass vs purity distinction. Both vials lost approximately 9–10% of recovered peptide mass over 90 days while HPLC purity remained approximately 99.6%. High chromatographic purity and loss of recovered mass are not mutually exclusive.

Test 473 — Multiple Refrigerated Vials N=1 per product

Diluent: Bacteriostatic water  |  Period: 90 days

Product Day 0 Mass Day 90 Mass Day 0 Purity Day 90 Purity
TCI Retatrutide 10 mg 11.18 mg 10.42 mg 99.31% 97.28%
XYX Retatrutide 12 mg 13.62 mg 13.14 mg 99.44% 97.09%
SSA Retatrutide 15 mg OUTLIER 16.61 mg 9.26 mg 98.17% 57.0%
Outlier — SSA 15 mg vial: One refrigerated SSA vial in Test 473 experienced substantial degradation by day 90, with recovered mass falling to 9.26 mg from 16.61 mg and HPLC purity dropping to 57.0%. This result stands in significant contrast to the other refrigerated samples tested. The cause cannot be determined from a single vial. Possible explanations discussed in the article include a closure defect, contamination, or an unstable formulation — however, N=1 means none of these can be established. Importantly, a later SSA batch (Test 555, 30 mg) did not reproduce this failure and maintained greater than 99.4% purity through 60 days. This result should not be interpreted as evidence that SSA material is generally unstable.

Bacteriostatic Water vs Ultrapure Water (Test 683)

Two vials from the same J5-ZYH Retatrutide 60 mg kit were prepared side-by-side and stored in the same refrigerator, tested on the same days. One was reconstituted in Hospira bacteriostatic water; one in ultrapure preservative-free water.

Bacteriostatic Water (Hospira)

63.40 mg
−2.4% over 90 days
Day 0: 64.98 mg → Day 90: 63.40 mg

Ultrapure Preservative-Free Water

67.69 mg
−7.9% over 90 days
Day 0: 73.48 mg → Day 90: 67.69 mg
Interpretation: An analytically interesting same-kit comparison that favoured bacteriostatic water in the tested samples, but which requires further replication before a general conclusion can be established. Each condition involved only one vial, and the starting measured peptide amounts differed between samples. This result should not be interpreted as proof that bacteriostatic water universally improves retatrutide stability.

Room-Temperature Solution Data (Test 715)

Two products were maintained in bacteriostatic water solution at room temperature for 45 days. The two samples behaved materially differently.

Product Day 0 Mass Day 45 Mass Mass Loss
J5-ZYH Retatrutide 60 mg N=1 77.11 mg 75.91 mg −1.6%
QSC Retatrutide 15 mg N=1 14.29 mg 13.04 mg −8.7%

The article also reports considerable fluctuation in purity measurements across timepoints. One vial recorded 95.7% purity at Day 28 and 99.5% at Day 45 — illustrating the degree of analytical variability present and one reason the authors considered recovered mass particularly informative for solution-state stability assessment.

These results describe what was analytically observed in the specific samples tested. They do not constitute a recommendation or assessment of any storage condition.

Refrigeration vs Freeze-Thaw Conditions (Tests 616 and 624)

Tests 616 and 624 used the same GBBB-ZJC Retatrutide 60 mg product, making this a more meaningful within-product comparison than cross-vendor analyses. This experiment concerns retatrutide in solution only and does not establish that freezing dry lyophilised retatrutide has the same effect.

Condition Test Period Recovered Mass Retained HPLC Purity
Steady refrigeration — Vial 1 616 90 days 91.0% Approx. 99.5%
Steady refrigeration — Vial 2 616 90 days 90.4% Approx. 99.5%
Freeze then thaw + refrigerate — Vial 1 624 45 days 85.6% Approx. 99.5%
Repeated freeze-thaw cycling — Vial 2 624 45 days 86.6% Approx. 99.5%
In this same-product comparison, freezing or repeated freeze-thaw cycling of the solution did not improve recovered peptide retention relative to steady refrigeration. The frozen/freeze-thaw conditions showed approximately 13–14% mass loss over 45 days, while steady refrigeration showed approximately 9–10% mass loss over 90 days. As with other tests, HPLC purity remained approximately 99.5% across all conditions despite the differing mass retention — again demonstrating that high purity does not preclude loss of recoverable peptide mass.

Lyophilised Long-Term Storage (Test 625)

Three sealed lyophilised retatrutide samples from different vendors were retested after extended storage. Small positive changes in measured mass are interpreted as normal analytical measurement variance and do not represent actual increases in peptide content.

Product Storage Interval Initial Purity Final Purity Mass Change
GYC R15 — grey cap ~14 months 99.49% 99.62% +1.2 mg (measurement variance)
QSC R15 — black cap ~21 months 98.32% 99.25% +0.5 mg (measurement variance)
CA R12 — clear top ~18 months 99.82% 99.67% +0.28 mg (measurement variance)
No meaningful degradation was detected in the three dry lyophilised samples tested over approximately 14–21 months. These are observational analytical findings from three specific samples stored under undisclosed conditions. They do not establish a universal shelf-life specification, expiry period, or storage guarantee for retatrutide.

High-Temperature Experiment: 130°F / ~54°C (Test 293)

Vacuum-sealed lyophilised QSC R15 retatrutide vials were maintained at 130°F (approximately 54°C). A refrigerated control from the same lot was analysed. Analytical testing by Janoshik.

Condition Recovered Mass HPLC Purity
Refrigerated control (no heat) 14.04 mg 96.958%
7 days at 130°F / ~54°C 13.93 mg 94.851%
14 days at 130°F / ~54°C 13.98 mg 94.099%
21 days at 130°F / ~54°C 13.97 mg 93.672%

Under sustained 130°F / approximately 54°C exposure, the tested lyophilised sample showed progressive chromatographic purity loss while measured mass remained broadly stable. The article estimates the purity decline at approximately 0.15 percentage points per day during continuous exposure at this temperature. These findings relate to one specific lot under controlled experimental conditions.

What the Analytical Data Suggests

The following observations are supported by the data as reported. They should not be interpreted as universal stability specifications.

  1. The tested dry lyophilised samples showed substantially greater apparent stability than solution-state samples under the conditions examined.
  2. Most refrigerated solution samples experienced comparatively modest loss of recovered peptide over the periods tested.
  3. Solution-state loss of recovered peptide could occur while HPLC purity remained very high.
  4. In Test 683, the bacteriostatic-water sample retained more measured peptide over 90 days than the ultrapure-water sample from the same kit.
  5. That bacteriostatic-water comparison involved only one vial per condition and does not establish a universal effect.
  6. The two room-temperature samples in Test 715 behaved materially differently from one another.
  7. In the same-product Tests 616 and 624 comparison, frozen and freeze-thaw solution samples did not outperform steadily refrigerated samples in recovered peptide retention.
  8. A major single-vial degradation event occurred in the refrigerated SSA 15 mg sample in Test 473.
  9. That SSA result was not reproduced in a later SSA 30 mg batch tested through 60 days (Test 555).
  10. No meaningful degradation was detected in the three dry lyophilised samples in Test 625 over approximately 14–21 months.
  11. Sustained 130°F / approximately 54°C exposure caused progressive chromatographic purity loss in the tested dry sample while measured mass remained broadly stable.

Study Limitations

Mostly N=1 per condition. Most experimental conditions involved a single vial. Individual-vial variation cannot reliably be separated from the effect of the experimental condition. Results from one vial cannot be assumed to represent a general outcome.

Not one formal stability programme. The eight studies were not a single controlled pharmaceutical stability programme. They occurred at different times involving different vendors, lots, nominal quantities, conditions and testing intervals. Comparisons involving the same product or kit — particularly Tests 616 vs 624 and the two arms of Test 683 — are therefore generally more informative than comparisons across unrelated tests.

Mass and purity measure different things. Recovered peptide mass and HPLC purity are distinct measurements. A sample can lose recovered mass while remaining highly pure, or maintain similar mass while purity declines. Do not combine them into a single generic percentage.

Filtration. Solution samples may undergo filtration before analytical testing. Aggregated or insoluble degradation material can potentially be removed, meaning the remaining soluble fraction may show high chromatographic purity even though total recovered peptide has fallen.

Measurement variance. Analytical assays have inherent measurement variability, illustrated by apparent small mass increases in Test 625 and purity fluctuations in Test 715. Small apparent increases should not be interpreted as creation of peptide.

Vendor and lot specificity. Results relate only to the particular materials tested. They cannot automatically be extrapolated to other manufacturers, batches, formulations, excipients, or Solatide products.

No validated universal shelf life. The data does not establish a universal 45-day, 60-day, 90-day, 14-month, 18-month or 21-month retatrutide shelf life. Results are described as observed in the samples tested, under the tested conditions.

Solatide Biosciences Quality Context

The external research summarised on this page is independent of Solatide Biosciences. Solatide products are supplied for in vitro laboratory research use only. Batch quality documentation may include, where performed and available:

  • HPLC-UV purity analysis
  • LC-MS identity confirmation
  • Amino acid analysis
  • Endotoxin screening
  • Independent third-party analytical reports

For batch-specific analytical data, refer to the COA library. For information on testing processes, visit the laboratory testing page.

These pages serve separate purposes and are not merged with or replaced by this research summary.

Source & Attribution

PepRecon. "Retatrutide: The Complete Stability Picture." Published 13 September 2026.
https://www.peprecon.com/research/retatrutide-stability/

The underlying data was generated through PTDS community-funded testing. PepRecon is the host and publisher of these findings. Independent third-party analytical laboratories were used for testing. Janoshik is specifically identified as the analytical laboratory for Test 293. PepRecon is an independent research and education platform and is not a laboratory, university, pharmaceutical company, research institute or peer-reviewed journal.

Solatide Biosciences is not affiliated with PepRecon or PTDS. External analytical data is presented for research and educational reference only and does not constitute an endorsement of any third-party product, service or finding. Independent research findings should be evaluated critically and in the context of their stated methodology and limitations.

All Solatide Biosciences products are for in vitro laboratory research use only and are not approved for human or veterinary use.